TR201914043A1 - EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN - Google Patents
EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMINInfo
- Publication number
- TR201914043A1 TR201914043A1 TR2019/14043A TR201914043A TR201914043A1 TR 201914043 A1 TR201914043 A1 TR 201914043A1 TR 2019/14043 A TR2019/14043 A TR 2019/14043A TR 201914043 A TR201914043 A TR 201914043A TR 201914043 A1 TR201914043 A1 TR 201914043A1
- Authority
- TR
- Turkey
- Prior art keywords
- metformin
- efervesan
- dapaglyflozin
- tablet formulations
- formulations containing
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003105 metformin Drugs 0.000 title abstract 3
- 239000007916 tablet composition Substances 0.000 title 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 abstract 2
- 229960003834 dapagliflozin Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007938 effervescent tablet Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Buluş, dapagliflozin veya dapagliflozinin farmasötik olarak kabul edilebilir bir tuzu ve metformin veya metforminin farmasötik olarak kabul edilebilir bir tuzu ile gerçekleştirilen efervesan tablet formülasyonlar ile ilgilidir.The invention relates to effervescent tablet formulations made with dapagliflozin or a pharmaceutically acceptable salt of dapagliflozin and metformin or a pharmaceutically acceptable salt of metformin.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
EP20866500.0A EP4031122A4 (en) | 2019-09-16 | 2020-08-05 | Effervescent tablet formulations comprising dapagliflozin and metformin |
PCT/TR2020/050687 WO2021054912A1 (en) | 2019-09-16 | 2020-08-05 | Effervescent tablet formulations comprising dapagliflozin and metformin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201914043A1 true TR201914043A1 (en) | 2021-04-21 |
Family
ID=74883168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4031122A4 (en) |
TR (1) | TR201914043A1 (en) |
WO (1) | WO2021054912A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4079296A1 (en) * | 2021-04-21 | 2022-10-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038979A1 (en) * | 2005-09-22 | 2007-04-12 | Swissco Development Ag | Effervescent metformin composition and tablets and granules made therefrom |
PT2498758T (en) * | 2009-11-13 | 2018-10-23 | Astrazeneca Uk Ltd | Bilayer tablet formulations |
EP2809311A1 (en) * | 2012-01-31 | 2014-12-10 | Mahmut Bilgic | Effervescent tablet formulations comprising the combination of voglibose and metformin |
WO2017098481A1 (en) * | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
WO2018185669A1 (en) * | 2017-04-07 | 2018-10-11 | Zenvision Pharma Llp | Effervescent compositions comprising saxagliptin or salt thereof |
-
2019
- 2019-09-16 TR TR2019/14043A patent/TR201914043A1/en unknown
-
2020
- 2020-08-05 WO PCT/TR2020/050687 patent/WO2021054912A1/en unknown
- 2020-08-05 EP EP20866500.0A patent/EP4031122A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021054912A1 (en) | 2021-03-25 |
EP4031122A4 (en) | 2023-08-30 |
EP4031122A1 (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201916829A2 (en) | DUAL-LAYER TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN | |
MX2022000711A (en) | Parp1 inhibitors. | |
DOP2020000102A (en) | HELPFUL COMPOUNDS TO INHIBIT CDK7 | |
PH12019550249A1 (en) | Solid compositions for oral administration | |
TN2017000495A1 (en) | Notch pathway signaling inhibitor compounds. | |
MX2017016802A (en) | Pharmaceutical formulations. | |
MX2020005483A (en) | Ildr2 antagonists and combinations thereof. | |
MX2023013096A (en) | Pharmaceutical use of cyclic peptide compound. | |
ZA202006377B (en) | Boronic acid derivatives and therapeutic uses thereof | |
MX2020010697A (en) | Kit, composition and combination therapy for fragile x syndrome. | |
CR20220355A (en) | Compounds active towards nuclear receptors | |
CL2020002199A1 (en) | Methylactam ring compound and pharmaceutical use thereof. | |
GEP20237486B (en) | Formulations of copanlisib | |
TR201914043A1 (en) | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN | |
PH12018501758A1 (en) | Oritavancin formulations | |
PH12020551985A1 (en) | Anti-human tlr7 antibody | |
TR201913472A2 (en) | A combination comprising vildagliptin and metformin | |
EA201890929A1 (en) | LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE | |
TR201914406A2 (en) | SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT | |
MX2021003830A (en) | Therapeutic uses of glucagon and combined product comprising same. | |
TR201722367A2 (en) | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE | |
TR201713954A2 (en) | PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRISITABIN AND EAVIRENZINE | |
TR201619184A2 (en) | DONEPESIL AND MEMANTINE CONTAINING CAPSULES | |
BR112022012584A2 (en) | SUBSTITUTED HYDROXYSTIBENE COMPOUNDS AND DERIVATIVES, SYNTHESIS AND USE OF THEM | |
EA201691422A1 (en) | ORIGINALLY FALLING TABLETED MEMANTINE COMPOSITIONS |